Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study

Video

Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.

Related Videos
Arlene O. Siefker-Radtke, MD
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Jonathan E. Rosenberg, MD
Joaquim Bellmunt, MD, PhD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Vikram Narayan, MD
Related Content
Oluwaseun Orikogbo, MD

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Vikram Narayan, MD

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC

May 5th 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
Seth P. Lerner, MD

Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer

May 3rd 2024
Article
Joseph Jacob, MD, MCR, of SUNY Upstate Medical University Hospital

TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC

May 3rd 2024
Article